Monocentric, double blinded, placebo controlled, randomized parallel study to evaluate the effect of INDUS1520 and INDUS1530 on facial skin and their in- use tolerance in women

Indus Biotech Private Limited0 个研究点目标入组 72 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a)Voluntary women from 35 years to 55 years of age.
•b)Participants with mild (Fine wrinkles and less number of lines) to moderate (Fine to moderate depth wrinkles with moderate number of lines) wrinkles in crowâ??s feet area
•c)Participants with photo type III (Light brown, sometimes burn, Difficult to tan) and IV (Moderate brown, rare burn, tan with ease) as per the Fitzpatrick scale.
•d)Having healthy skin on face.
•e)Willingness to discontinue the use of other cosmetic products on face during the course of the study.
•f)Accepting not to use products with the same end benefit during the entire study duration.
•g)Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures.
•h)Having signed a Consent Form, after being informed orally and in writing of all information concerning the study procedures and study objectives.
•i)Willingness to avoid intense UV exposure as far as possible for the entire study duration

•a)Pregnant women by UPT / lactating women / women planning pregnancy.
•b)Any skin disease on face
•c)Any cutaneous conditions on test site (scars, moles, papules etc).
•d)Hypersensitivity, allergy antecedent (to any cosmetic product, raw material).
•e)Chronic illness which may influence the study results.
•f)Any clinically significant systemic or cutaneous disease, which may interfere with study procedures.
•g)For whom the Investigator considers that he/she will not be compliant with study procedures.
•h)Participants on any medical treatment either systemic or topical which may interfere with the performance of the study treatment (presently or in the past 1 month).
•i)Subject in an exclusion period or already participating in another similar cosmetic or therapeutic trial as identified during screening on visit 1 (V1).

发起方

Indus Biotech Private Limited